granted
on 09 Feb 2024
Last Applicant/ Owned by
230 East Grand Avenue, Suite 200
South San Francisco
CA
94080
Serial Number
97035820 filed on 20th Sep 2021
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
The English translation of "TERREMOTO" in the mark is "earthquake". pharmaceuticals for the prevention and treatment of cancer, oncological diseases, disorders and conditions; pharmaceuticals for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidneRead More
pharmaceuticals for the prevention and treatment of cancer, oncological diseases, disorders and conditions; pharmaceuticals for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; pharmaceutical preparations and substances for the prevention and treatment of cancer, oncological diseases, disorders and conditions;pharmaceutical preparations and substances for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; biopharmaceuticals for the prevention and treatment of cancer, oncological diseases, disorders and conditions; biopharmaceuticals for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; medicines for the prevention and treatment of cancer, oncological diseases, disorders and conditions; medicines for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; drugs for the prevention and treatment of cancer, oncological diseases, disorders and conditions;drugs for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; drug compounds for the prevention and treatment of cancer, oncological diseases, disorders and conditions;drug compounds for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; small molecules for the prevention and treatment of cancer, oncological diseases, disorders and conditions;small molecules for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; therapeutics for the prevention and treatment of cancer, oncological diseases, disorders and conditions;therapeutics for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions
No 97035820
No Service/Collective Mark
No T-4762/2 US
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 10th Feb 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 09th Feb 2024 | SOU TEAS EXTENSION RECEIVED |
| 09th Feb 2024 | SOU EXTENSION 1 FILED |
| 09th Feb 2024 | SOU EXTENSION 1 GRANTED |
| 15th Aug 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 20th Jun 2023 | PUBLISHED FOR OPPOSITION |
| 20th Jun 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 31st May 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 11th May 2023 | EXAMINERS AMENDMENT -WRITTEN |
| 11th May 2023 | EXAMINERS AMENDMENT E-MAILED |
